Myambutol label

Myambutol

Myambutol Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

MYAMBUTOL may produce decreases in visual acuity which appear to be due to optic neuritis. This effect may be related to dose and duration of treatment. This effect is generally reversible when administration of the drug is discontinued promptly. However, irreversible blindness has been reported. (See PRECAUTIONSand ADVERSE REACTIONS).

Liver toxicities including fatalities have been reported (See ADVERSE REACTIONS). Baseline and periodic assessment of hepatic function should be performed.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

MYAMBUTOL is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in-vitro susceptibility studies. In patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following:

  • MYAMBUTOL plus isoniazid

  • MYAMBUTOL plus isoniazid plus streptomycin.

In patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. Consequently, in such retreatment patients, MYAMBUTOL should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in-vitro studies. Antituberculous drugs used with MYAMBUTOL have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilized.

History

There is currently no drug history available for this drug.

Other Information

MYAMBUTOL ethambutol hydrochloride is an oral chemotherapeutic agent which is specifically effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. The structural formula is:

Structural Formula

MYAMBUTOL 100 and 400 mg tablets contain the following inactive ingredients:  Gelatin, Hydroxypropyl Methylcellulose, Magnesium Stearate, Sodium Lauryl Sulfate, Sorbitol, Stearic Acid, Sucrose, Titanium Dioxide and other ingredients.

Myambutol Manufacturers

  • Physicians Total Care, Inc.
    Myambutol | Physicians Total Care, Inc.
    No Recall

    Myambutol | Physicians Total Care, Inc.

    Myambutol | Physicians Total Care, Inc.
    MYAMBUTOL should not be used alone, in initial treatment or in retreatment. MYAMBUTOL should be administered on a once every 24-hour basis only. Absorption is not significantly altered by administration with food. Therapy, in general, should be continued until bacteriological conversion has become permanent and maximal clinical improvement has occurred.

    MYAMBUTOL is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established. Initial Treatment:

    Initial Treatment:

    In patients who have not received previous antituberculous therapy, administer MYAMBUTOL 15 mg/kg (7 mg/ lb) of body weight, as a single oral dose once every 24 hours. In the more recent studies, isoniazid has been administered concurrently in a single, daily, oral dose.

    Retreatment: Retreatment:

    In patients who have received previous antituberculous therapy, administer MYAMBUTOL 25 mg/kg (11 mg/lb) of body weight, as a single oral dose once every 24 hours. Concurrently administer at least one other antituberculous drug to which the organisms have been demonstrated to be susceptible by appropriate in-vitro tests. Suitable drugs usually consist of those not previously used in the treatment of the patient. After 60 days of MYAMBUTOL administration, decrease the dose to 15 mg/kg (7mg/ lb) of body weight, and administer as a single oral dose once every 24 hours.

    During the period when a patient is on a daily dose of 25 mg/kg, monthly eye examinations are advised.

    See Table for easy selection of proper weight-dose tablet(s). Weight-Dose Table      15 mg/kg (7 mg/lb) Schedule  Weight Range  Daily Dose  Pounds    Kilograms  In mg  Under 85 lbs.    Under 37 kg  500  85 - 94.5    37 – 43  600  95 - 109.5    43 – 50  700  110 - 124.5    50 – 57  800  125 - 139.5    57 – 64  900  140 - 154.5    64 – 71  1000  155 - 169.5    71 – 79  1100  170 - 184.5    79 – 84  1200  185 - 199.5    84 – 90  1300  200 - 214.5    90 – 97  1400  215 and Over    Over 97  1500      25 mg/kg (11 mg/lb) Schedule  Under 85 lbs.    Under 38 kg  900  85 - 92.5    38 - 42  1000  93 - 101.5    42 - 45.5  1100  102 - 109.5    45.5 – 50  1200  110 - 118.5    50 – 54  .1300  119 - 128.5    54 – 58  1400  129 - 136.5    58 – 62  1500  137 - 146.5    62 – 67  1600  147 - 155.5    67 – 71  1700  156 - 164.5    71 – 75  1800  165 - 173.5    75 – 79  1900  174 - 182.5    79 – 83  2000  183 - 191.5    83 – 87  2100  192 - 199.5    87 – 91  2200  200 - 209.5    91 – 95  2300  210 - 218.5    95 – 99  2400  219 and Over    Over 99  2500
  • Sti Pharma, Llc
    Myambutol | Sun Pharma Global Fze
    No Recall

    Myambutol | Sun Pharma Global Fze

    Myambutol | Sun Pharma Global Fze

    Prior to initiation of caffeine citrate, baseline serum levels of caffeine should be measured in infants previously treated with theophylline, since preterm infants metabolize theophylline to caffeine. Likewise, baseline serum levels of caffeine should be measured in infants born to mothers who con­sumed caffeine prior to delivery, since caffeine readily crosses the placenta.


    The recommended loading dose and maintenance doses of caffeine citrate follow.


    * using a syringe infusion pump † beginning 24 hours after the loading dose  
    Dose of Caffeine Citrate
    Dose of Caffeine Citrate
    Route
    Frequency
     
    Volume
    mg/kg
     
     
    Loading Dose
    1 mL/kg
    20 mg/kg
    Intravenous*
    One Time
     
     
     
    (over 30
     
     
     
     
    minutes)
     
    Maintenance
    0.25 mL/kg
    5 mg/kg
    Intravenous*
    Every
    Dose
     
     
    (over 10
    24 hours†
     
     
     
    minutes) or
     
     
     
     
    Orally
     

    NOTE THAT THE DOSE OF CAFFEINE BASE IS ONE-HALF THE DOSE WHEN EXPRESSED AS CAFFEINE CITRATE (e.g., 20 mg of caffeine citrate is equiva­lent to 10 mg of caffeine base).


    Serum concentrations of caffeine may need to be monitored periodically throughout treatment to avoid toxicity. Serious toxicity has been associated with serum levels greater than 50 mg/L.


    Caffeine citrate injection and caffeine citrate oral solution should be inspected visually for particulate matter and discoloration prior to administration. Vials containing discolored solution or visible particulate matter should be discarded.



    Drug Compatibility

    To test for drug compatibility with common intravenous solutions or medica­tions, 20 mL of caffeine citrate injection were combined with 20 mL of a solution or medication, with the exception of an Intralipid® admixture, which was combined as 80 mL/80 mL. The physical appearance of the com­bined solutions was evaluated for precipitation. The admixtures were mixed for 10 minutes and then assayed for caffeine. The admixtures were then continu­ally mixed for 24 hours, with further sampling for caffeine assays at 2, 4, 8, and 24 hours.


    Based on this testing, caffeine citrate injection, 60 mg/3 mL is chemically stable for 24 hours at room temperature when combined with the following test products.

    Dextrose Injection, USP 5% 50% Dextrose Injection USP Intralipid® 20% IV Fat Emulsion Aminosyn® 8.5% Crystalline Amino Acid Solution Dopamine HCI Injection, USP 40 mg/mL diluted to 0.6 mg/mL with Dextrose Injection, USP 5% Calcium Gluconate Injection, USP 10% (0.465 mEq/Ca+2/mL) Heparin Sodium Injection, USP 1000 units/mL diluted to 1 unit/mL with Dextrose Injection, USP 5%

    Fentanyl Citrate Injection, USP 50 µg/mL diluted to 10 µg/mL with Dextrose Injection, USP 5%

  • Myambutol | Ax Pharmaceutical Corp
    No Recall

    Myambutol | Ax Pharmaceutical Corp

    Myambutol | Ax Pharmaceutical Corp

    There is currently no dosage information available for this product. We apologize for any inconvenience.

  • Myambutol | A-s Medication Solutions Llc
    No Recall

    Myambutol | A-s Medication Solutions Llc

    Myambutol | A-s Medication Solutions Llc

    MYAMBUTOL should not be used alone, in initial treatment or in retreatment. MYAMBUTOL should be administered on a once every 24-hour basis only. Absorption is not significantly altered by administration with food. Therapy, in general, should be continued until bacteriological conversion has become permanent and maximal clinical improvement has occurred.

    MYAMBUTOL is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established.

    Initial Treatment: In patients who have not received previous antituberculous therapy, administer MYAMBUTOL 15 mg/kg (7 mg/ lb) of body weight, as a single oral dose once every 24 hours. In the more recent studies, isoniazid has been administered concurrently in a single, daily, oral dose.

    Retreatment:

    Retreatment:

    In patients who have received previous antituberculous therapy, administer MYAMBUTOL 25 mg/kg (11 mg/lb) of body weight, as a single oral dose once every 24 hours. Concurrently administer at least one other antituberculous drug to which the organisms have been demonstrated to be susceptible by appropriate in-vitro tests. Suitable drugs usually consist of those not previously used in the treatment of the patient. After 60 days of MYAMBUTOL administration, decrease the dose to 15 mg/kg (7mg/ lb) of body weight, and administer as a single oral dose once every 24 hours.

    During the period when a patient is on a daily dose of 25 mg/kg, monthly eye examinations are advised.

    See Table for easy selection of proper weight-dose tablet(s).

    Weight-Dose Table         15 mg/kg (7 mg/lb) Schedule   Weight Range   Daily Dose   Pounds      Kilograms   In mg   Under 85 lbs.      Under 37 kg   500   85 - 94.5      37 – 43   600   95 - 109.5      43 – 50   700   110 - 124.5      50 – 57   800   125 - 139.5      57 – 64   900   140 - 154.5      64 – 71   1000   155 - 169.5      71 – 79   1100   170 - 184.5      79 – 84   1200   185 - 199.5      84 – 90   1300   200 - 214.5      90 – 97   1400   215 and Over      Over 97   1500         25 mg/kg (11 mg/lb) Schedule   Under 85 lbs.      Under 38 kg   900   85 - 92.5      38 - 42   1000   93 - 101.5      42 - 45.5   1100   102 - 109.5      45.5 – 50   1200   110 - 118.5      50 – 54   .1300   119 - 128.5      54 – 58   1400   129 - 136.5      58 – 62   1500   137 - 146.5      62 – 67   1600   147 - 155.5      67 – 71   1700   156 - 164.5      71 – 75   1800   165 - 173.5      75 – 79   1900   174 - 182.5      79 – 83   2000   183 - 191.5      83 – 87   2100   192 - 199.5      87 – 91   2200   200 - 209.5      91 – 95   2300   210 - 218.5      95 – 99   2400   219 and Over      Over 99   2500